Fuller & Thaler Asset Management Inc. Acquires 274,192 Shares of Encompass Health Co. (NYSE:EHC)

Fuller & Thaler Asset Management Inc. raised its position in Encompass Health Co. (NYSE:EHC - Free Report) by 24.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,378,077 shares of the company's stock after buying an additional 274,192 shares during the quarter. Fuller & Thaler Asset Management Inc. owned about 1.37% of Encompass Health worth $127,265,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in EHC. Morse Asset Management Inc acquired a new stake in Encompass Health in the third quarter valued at about $68,000. Tidal Investments LLC boosted its stake in shares of Encompass Health by 5.7% in the 3rd quarter. Tidal Investments LLC now owns 3,509 shares of the company's stock valued at $339,000 after purchasing an additional 188 shares in the last quarter. Synovus Financial Corp grew its holdings in shares of Encompass Health by 92.9% during the 3rd quarter. Synovus Financial Corp now owns 16,057 shares of the company's stock valued at $1,552,000 after purchasing an additional 7,733 shares during the last quarter. Franklin Resources Inc. increased its position in Encompass Health by 22.0% during the 3rd quarter. Franklin Resources Inc. now owns 700,021 shares of the company's stock worth $67,412,000 after purchasing an additional 126,000 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Encompass Health by 22.1% in the 4th quarter. GAMMA Investing LLC now owns 1,947 shares of the company's stock valued at $180,000 after purchasing an additional 352 shares during the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Trading Up 0.6 %

Encompass Health stock traded up $0.67 during mid-day trading on Monday, hitting $114.04. 446,951 shares of the stock were exchanged, compared to its average volume of 674,871. The firm's fifty day simple moving average is $100.08 and its two-hundred day simple moving average is $98.57. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a 12 month low of $82.38 and a 12 month high of $115.48. The stock has a market capitalization of $11.48 billion, a price-to-earnings ratio of 25.55, a PEG ratio of 2.31 and a beta of 0.87.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The business had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.43 billion. During the same quarter in the prior year, the firm posted $1.12 earnings per share. The business's quarterly revenue was up 10.6% compared to the same quarter last year. Analysts forecast that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st were given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend was Tuesday, April 1st. Encompass Health's dividend payout ratio (DPR) is 15.25%.

Insider Buying and Selling at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 2.10% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on EHC. Royal Bank of Canada upped their price target on shares of Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday. Barclays increased their target price on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research report on Friday. KeyCorp boosted their price target on Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a report on Friday. William Blair reiterated an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. Finally, Truist Financial reissued a "buy" rating and set a $135.00 target price (up from $116.00) on shares of Encompass Health in a report on Monday. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $118.00.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.